tailieunhanh - Báo cáo y học: " Clostridium difficile: moving beyond antimicrobial therapy"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học quốc tế cung cấp cho các bạn kiến thức về ngành y đề tài: Clostridium difficile: moving beyond antimicrobial therapy. | Adalja and Kellum Critical Care 2010 14 320 http content 14 5 320 CRITICAL CARE JOURNAL CLUB CRITIQUE L Clostridium difficile moving beyond antimicrobial therapy Amesh A Adalja1 2 and John A Kellum 1 University of Pittsburgh Department of Critical Care Medicine Evidence-Based Medicine Journal Club edited by Sachin Yende Expanded abstract Citation Lowy I Molrine DC Leav BA Blair BM Baxter R Gerding DN Nichol G Thomas WD Jr. Leney M Sloan S Hay CA Ambrosino DM Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010 362 197-205. Background New therapies are needed to manage the increasing incidence severity and high rate of recurrence of Clostridium difficile infection. Methods Objective To assess the ability of monoclonal antibodies directed against two toxins of to prevent recurrence of disease. Design Randomized double-blind placebo-controlled study Setting 30 medical centers in the United States and Canada Subjects 200 subjects with diarrhea and a positive stool toxin assay for cile being treating with metronidazole or vancomycin Intervention Antibodies administered together as a single infusion each at a dose of 10 mg per kilogram of body weight Outcomes The primary outcome was laboratory-documented recurrence of infection during the 84 days after the administration of monoclonal antibodies or placebo. Results Among the 200 patients who were enrolled 101 in the antibody group and 99 in the placebo group the rate of Correspondence kellumja@ 6th Floor Scaife Hall 3550 Terrace Street University of Pittsburgh Pittsburgh PA 1 5261 USA Full list of author information is available at the end of the article 2 BioMed Central 2010 BioMed Central Ltd recurrence of C. diffi cile infection was lower among patients treated with monoclonal antibodies 7 vs. 25 95 confidence interval 7 to 29 P . The absolute risk reduction ARR was 16 yielded a number needed to treat NNT of .

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.